GLP1R and obesity due to melanocortin 4 receptor deficiency: It is unclear why GLP-1 RA use was higher among women in the present study; it may reflect the well-documented higher rates of contact with the health care system among female patients.27 In addition to the cardiovascular benefits, GLP-1 RAs have also been shown to cause significant and sustained weight loss.28 It is possible that female patients with T2D may engage more with a nutritionist and may be more likely to seek pharmacotherapy for medical management of obesity, which may include counseling for GLP-1 RA use.29